A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Hata T, Fukunaga M, Murata K, Uemura Y, Fukuzaki T, Ota H, Ohue M, Ohnishi T, Tanaka N, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M.
Hata T, et al. Among authors: ohnishi t.
Cancer Chemother Pharmacol. 2013 Jun;71(6):1657-63. doi: 10.1007/s00280-013-2143-8. Epub 2013 Mar 31.
Cancer Chemother Pharmacol. 2013.
PMID: 23543294
Clinical Trial.